Avascular osteonecrosis of the jaws induced by diphosphonates [3];Ostéonécrose avasculaire de la machoire sous diphosphonates

Therapie

Volumn 61, Issue 4, 2006, Pages 363-365

  Lannoy, Damien ^a   Decaudin, Bertrand ^a   Barrier, Frédérique ^a   Bemba, Maxime ^a   Wierre, Laurence ^a   Pignon, Jean Michel ^a   Horrent, Sandrine ^a   Résibois, Jean Pierre ^a   Wetterwald, Marc ^a   Odou, Pascal ^a,b  

^a Centre Hospitalier de Dunkerque   (France)

^b UNIV LILLE   (France)

Author keywords

Disphosphonates; Osteonecrosis; Zoledronic acid

Indexed keywords

ALPRAZOLAM; BISPHOSPHONIC ACID DERIVATIVE; BROMAZEPAM; CARBAMAZEPINE; CLODRONIC ACID; CLOMIPRAMINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; LYTOS; MELPHALAN; MORPHINE; PAMIDRONIC ACID; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; VALACICLOVIR; VINCRISTINE; ZOLEDRONIC ACID; ZOLPIDEM TARTRATE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; AVASCULAR NECROSIS; BIOPSY; CASE REPORT; CORTICOSTEROID THERAPY; FEMALE; HEMATOLOGY; HUMAN; JAW; LETTER; MANDIBLE; MYELOMA; PATIENT SATISFACTION; PRIORITY JOURNAL; RADIOGRAPHY; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; JAW DISEASE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA;

AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; PLASMACYTOMA;

EID: 36549012221     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006061     Document Type: Article

References (13)

1. Obrist R, Hartmann D, Obrecht JP. Osteonecrosis after chemotherapy. Lancet 1978; 1: 1316
2. Marx RE. Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115-7
3. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28(5): 524-31
4. Kapitola J, Zak J, Lacinova Z et al. Effect of growth hormone and Pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 2000; 49(S1): S101-106
5. Ueland T. GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 2005; 152(3): 327-32
6. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9(8): 2893-7
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527-34
8. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182 (8): 413-5
9. Durie BGM, Katz M, Mc Coy J, et al. Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia® and Zometa® use. Blood 2004; 104: 756a
10. Ratti R, Farina G, Borgonovo K, et al. Recurrent alveolar abscesses by bisphosphonates. J Clin Oncol 2005; 23(16S): 243s [Abstract]
11. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117(6): 440-1
12. Migliatori CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21(22): 4253-4
13. Wang J, Godger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61(9): 1104-7